Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Beneficial Effects of novel Aureobasidium Pullulans strains produced Beta-1,3-1,6 Glucans on Interleukin-6 and D-Dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study

Kadalraja Raghavan, Vidyasagar Devaprasad Dedeepiya, Vaddi Suryaprakash, Kosagi-Sharaf Rao, Nobunao Ikewaki, Tohru Sonoda, Gary A. Levy, Masaru Iwasaki, Rajappa Senthilkumar, Senthilkumar Preethy, View ORCID ProfileSamuel JK Abraham
doi: https://doi.org/10.1101/2021.08.09.21261738
Kadalraja Raghavan
1Dept of Paediatric Neurology, Kenmax Healthcare Services Pvt Ltd, Madurai, India
2Research & Development Division, Sarvee Integra Pvt Ltd, Chennai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vidyasagar Devaprasad Dedeepiya
3Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vaddi Suryaprakash
4Department of Urology, Yashoda Hospitals, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kosagi-Sharaf Rao
5Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT AIP), City of Knowledge, Panama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nobunao Ikewaki
6Dept. of Medical Life Science, Kyushu University of Health and Welfare, Japan
7Institute of Immunology, Junsei Educational Institute, Nobeoka, Miyazaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tohru Sonoda
7Institute of Immunology, Junsei Educational Institute, Nobeoka, Miyazaki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary A. Levy
8Professor Emeritus, Medicine and Immunology, University of Toronto, Ontario, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masaru Iwasaki
9Centre for Advancing Clinical Research (CACR), University of Yamanashi - School of Medicine, Chuo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rajappa Senthilkumar
10Fujio-Eiji Academic Terrain (FEAT), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Senthilkumar Preethy
10Fujio-Eiji Academic Terrain (FEAT), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel JK Abraham
3Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India
9Centre for Advancing Clinical Research (CACR), University of Yamanashi - School of Medicine, Chuo, Japan
11Antony-Xavier Interdisciplinary Scholastics (AXIS), GN Corporation Co. Ltd., Kofu, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Samuel JK Abraham
  • For correspondence: drsam@nichimail.jp drspp@nichimail.jp
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Objective Cytokine storm and Coagulopathy have been implicated as major causes of morbidity and mortality in COVID-19 patients. A black yeast Aureobasidium pullulans AFO-202 strain produced beta 1,3-1,6 glucan has been reported to offer potential immune enhancement and metabolism balancing, as well as mitigation of coagulopathy risks. The N-163 strain produced beta glucan is an efficient anti-inflammatory immune modulator. In this pilot clinical study, we report the beneficial effects of these two beta glucans on the biomarkers for cytokine storm and coagulopathy in COVID-19 patients.

Methods A total of 24 RT-PCR positive COVID-19 patients were recruited (Age range: 18∼62; 17 males and 7 females). Patients were randomly divided into three groups (Gr): Gr. 1 control (n=8); Gr. 2: AFO-202 beta glucan (n=8); and Gr. 3, a combination of AFO-202 and N-163 beta glucans (n=8). All three groups received the standard care while groups 2 and 3 received additional supplementation of beta glucans for 30 days. In addition to basic clinical parameters, we periodically evaluated D-Dimer, IL-6, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), the neutrophil to lymphocyte ratio (NLR), the lymphocyte to CRP ratio (LCR) and the leukocyte-CRP ratio (LeCR).

Results The duration of hospital stay for all three groups was nearly equivalent. There was no mortality of the subjects in any of the groups. Intermittent oxygen was administered from day of admission for up to four to five days with mask (two to four Lpm) to two subjects in Gr. 2 and one subject in Gr. 3. None of the subjects required ventilation. The D-Dimer values in Gr. 1, which was on average 751 ng/ml at baseline, decreased to 143.89 ng/ml on day 15, but increased to 202.5 ng/ml on day 30, which in groups 2 and 3 decreased on day 15 and continued to remain at normal levels until day 30. IL-6 levels decreased on day 15 from an average of 7.395 pg/ml to 3.16 pg/ml in the control, 26.18 pg/ml to 6.94 pg/ml in Gr. 2 and 6.25 pg/ml to 5.22 pg/ml in Gr. 3. However, when measured on day 30, in Gr. 1, the IL-6 increased to 55.37 pg/ml while there was only slight marginal increase in Gr. 2 but within normal range, and the levels further decreased to less than 0.5 pg/ml in Gr. 3. The same trend was observed with ESR. LCR and LeCR increased significantly in Gr. 3. NLR decreased significantly in groups 2 and 3. There was no difference in CRP within the groups.

Conclusion In this exploratory study, consumption of Aureobasidium pullulans produced beta glucans for thirty days, results in a significant control of IL6, D-Dimer and NLR, a significant increase in LCR, LeCR and marginal control of ESR in COVID-19 patients. As these beta glucans are well known food supplements with decades of a track record for safety, based on these results, we recommend larger multi-centric clinical studies to validate their use as an adjunct in the management of COVID-19 and the ensuing long COVID-19 syndrome.

Competing Interest Statement

Author Samuel Abraham is a shareholder in GN Corporation, Japan which in turn is a shareholder in the manufacturing company of the Beta Glucans described in the study.

Clinical Trial

CTRI/2021/04/032766

Clinical Protocols

http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=54786&EncHid=&modid=&compid=%27,%2754786det%27

Funding Statement

No external funding was received for the study.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was registered in India clinical trial registry CTRI, Ref no CTRI 2021 04 032766. The study was approved by the Institutional Ethics Committee (IEC) of Shanmuga Medical Research Foundation Trust Institutional Ethics Committee, India on 29th March, 2021.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • (drkraghavan27{at}gmail.com), (dedeepiya_76{at}yahoo.co.in), (suryaprakashuro{at}gmail.com), (jrao{at}indicasat.org.pa, kjr5n2009{at}gmail.com), (nikewaki{at}phoenix.ac.jp), (sonodat{at}phoenix.ac.jp), (gary.levy{at}uhn.ca), (miwasaki{at}yamanashi.ac.jp), (rsk{at}nichimail.jp), (drspp{at}nichimail.jp), (drsam{at}nichimail.jp)

  • Funding: No external funding was received for the study.

  • Ethics Approval: The study was registered in India’s clinical trial registry CTRI, Ref no: CTRI/2021/04/032766 (http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=54786). The study was approved by the Institutional Ethics Committee (IEC) of Shanmuga Medical Research Foundation Trust-Institutional Ethics Committee, India on 29th March, 2021.

  • Potential Conflict of Interests: Author Samuel Abraham is a shareholder in GN Corporation, Japan which in turn is a shareholder in the manufacturing company of the Beta Glucans described in the study.

Data Availability

All data generated or analysed during this study are included in this manuscript.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted August 14, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Beneficial Effects of novel Aureobasidium Pullulans strains produced Beta-1,3-1,6 Glucans on Interleukin-6 and D-Dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Beneficial Effects of novel Aureobasidium Pullulans strains produced Beta-1,3-1,6 Glucans on Interleukin-6 and D-Dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study
Kadalraja Raghavan, Vidyasagar Devaprasad Dedeepiya, Vaddi Suryaprakash, Kosagi-Sharaf Rao, Nobunao Ikewaki, Tohru Sonoda, Gary A. Levy, Masaru Iwasaki, Rajappa Senthilkumar, Senthilkumar Preethy, Samuel JK Abraham
medRxiv 2021.08.09.21261738; doi: https://doi.org/10.1101/2021.08.09.21261738
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Beneficial Effects of novel Aureobasidium Pullulans strains produced Beta-1,3-1,6 Glucans on Interleukin-6 and D-Dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study
Kadalraja Raghavan, Vidyasagar Devaprasad Dedeepiya, Vaddi Suryaprakash, Kosagi-Sharaf Rao, Nobunao Ikewaki, Tohru Sonoda, Gary A. Levy, Masaru Iwasaki, Rajappa Senthilkumar, Senthilkumar Preethy, Samuel JK Abraham
medRxiv 2021.08.09.21261738; doi: https://doi.org/10.1101/2021.08.09.21261738

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (496)
  • Anesthesia (106)
  • Cardiovascular Medicine (1110)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (275)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (505)
  • Epidemiology (9796)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2327)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1567)
  • Health Policy (737)
  • Health Systems and Quality Improvement (608)
  • Hematology (238)
  • HIV/AIDS (508)
  • Infectious Diseases (except HIV/AIDS) (11669)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2154)
  • Nursing (134)
  • Nutrition (340)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (519)
  • Oncology (1185)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (221)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (314)
  • Pediatrics (699)
  • Pharmacology and Therapeutics (303)
  • Primary Care Research (268)
  • Psychiatry and Clinical Psychology (2195)
  • Public and Global Health (4685)
  • Radiology and Imaging (786)
  • Rehabilitation Medicine and Physical Therapy (458)
  • Respiratory Medicine (625)
  • Rheumatology (276)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (212)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)